Our preclinical anti-hepatitis drug development services range from screening libraries to the evaluation of the efficacy, toxicity and range of action of your compound. InPheno provides a HBV replication assay in which human hepatoma cells stably express and replicate a HBV genome.
Our assay for profiling drug candidates takes advantage of the flexibility of transiently transfecting a hepatoma cell line with a cloned and functional HBV genome. This clone can be modified to include mutations in the reverse transcriptase gene conferring resistance to current therapies or to include relevant viral segments of HBV isolated directly from patient-derived specimens. Detection of cytoplasmic viral DNA is quantified by a PCR-based assay.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.
